Figure 2 | Scientific Reports

Figure 2

From: First-in-class trispecific VHH-Fc based antibody with potent prophylactic and therapeutic efficacy against SARS-CoV-2 and variants

Figure 2

ABS-VIR-001 prevents SARS-CoV-2 infection and death and decreases viral burden in huACE-2 mice challenged with authentic SARS-CoV-2. Human ACE-2 expressing mice were challenged with SARS-CoV-2 (intranasally, I.N.) and were randomly divided into 4 groups and treated as indicated and observed for body weight and clinical symptoms. (A) Workflow of the SARS-CoV-2 animal study. B) On D3, the lungs of the mice were harvested and viral titers were assessed by RT-qPCR. Statistical significance was calculated by a student t-test and a P value of < 0.05 was considered statistically significant. This data shows that viral titer was not detected (3 out of the 4 mice in the prophylaxis Group 2) or significantly decreased in all mice treated with ABS-VIR-001, indicating that ABS-VIR-001 is a potent prophylactic and treatment for SARS-CoV-2 infection. (C) After D3, all mice within the I.P. Treatment group survived (Group 4) or showed similar survival (Groups 2 and 3) as the no treatment group (Group 1), indicating that ABS-VIR-001 is well-tolerated and more importantly, ABS-VIR-001 prevented death. The graphs were generated using the Prism (GraphPad) software v9.2.0 (https://www.graphpad.com/).

Back to article page